open access

Vol 49, No 3 (2017)
Original and clinical articles
Published online: 2017-07-05
Submitted: 2016-12-28
Accepted: 2017-04-14
Get Citation

Do bacteria isolated from ICU patients ‘ESKAPE’ antibiotic treatment? In vitro susceptibility of the Enterobacteriaceae family to tigecycline

Katarzyna Talaga-Ćwiertnia, Paweł Krzyściak, Małgorzata Bulanda
DOI: 10.5603/AIT.a2017.0034
·
Pubmed: 28712104
·
Anaesthesiol Intensive Ther 2017;49(3):210-214.

open access

Vol 49, No 3 (2017)
Original and clinical articles
Published online: 2017-07-05
Submitted: 2016-12-28
Accepted: 2017-04-14

Abstract

Background: Enterobacteriaceae are currently causing the majority of healthcare-associated infections (HAI) and
simultaneously expressing increasing levels of antibiotic resistance. The purpose of this study is to assess the in vitro
sensitivity of MDR strains from the family Enterobacteriaceae to tigecycline in relation to their origin from patients
hospitalized in intensive care units (ICUs) and non-ICUs.

Methods: The study involved 156 clinically significant strains of the Enterobacteriaceae family isolated from patients
with complicated intraabdominal infections (cIAIs) and/or complicated skin and skin structure infections (cSSSIs)
hospitalized in ICUs and other surgical departments. Tigecycline MICs were determined by Etest.

Results: The highest percentage of tigecycline non-susceptible (intermediate + resistant strains) in vitro strains
among the Enterobacteriaceae species were observed for Serratia spp. 77.3%, followed by Citrobacter spp. (76.9%)
and Enterobacter spp. (70%); whereas K. pneumoniae and E. coli showed 73–73.8% tigecycline susceptibility rates.

Conclusion: Tigecycline demonstrates a high level of antimicrobial in vitro activity when tested against E. coli and
K. pneumoniae, even those with the ESBL-phenotype. Tigecycline retained activity against merely 22–30% of Enterobacter, Citrobacter and Serratia genera.

Abstract

Background: Enterobacteriaceae are currently causing the majority of healthcare-associated infections (HAI) and
simultaneously expressing increasing levels of antibiotic resistance. The purpose of this study is to assess the in vitro
sensitivity of MDR strains from the family Enterobacteriaceae to tigecycline in relation to their origin from patients
hospitalized in intensive care units (ICUs) and non-ICUs.

Methods: The study involved 156 clinically significant strains of the Enterobacteriaceae family isolated from patients
with complicated intraabdominal infections (cIAIs) and/or complicated skin and skin structure infections (cSSSIs)
hospitalized in ICUs and other surgical departments. Tigecycline MICs were determined by Etest.

Results: The highest percentage of tigecycline non-susceptible (intermediate + resistant strains) in vitro strains
among the Enterobacteriaceae species were observed for Serratia spp. 77.3%, followed by Citrobacter spp. (76.9%)
and Enterobacter spp. (70%); whereas K. pneumoniae and E. coli showed 73–73.8% tigecycline susceptibility rates.

Conclusion: Tigecycline demonstrates a high level of antimicrobial in vitro activity when tested against E. coli and
K. pneumoniae, even those with the ESBL-phenotype. Tigecycline retained activity against merely 22–30% of Enterobacter, Citrobacter and Serratia genera.

Get Citation

Keywords

intensive care unit; Enterobacteriaceae, infections; ESBL; AmpC; MBL; in vitro activity

About this article
Title

Do bacteria isolated from ICU patients ‘ESKAPE’ antibiotic treatment? In vitro susceptibility of the Enterobacteriaceae family to tigecycline

Journal

Anaesthesiology Intensive Therapy

Issue

Vol 49, No 3 (2017)

Pages

210-214

Published online

2017-07-05

DOI

10.5603/AIT.a2017.0034

Pubmed

28712104

Bibliographic record

Anaesthesiol Intensive Ther 2017;49(3):210-214.

Keywords

intensive care unit
Enterobacteriaceae
infections
ESBL
AmpC
MBL
in vitro activity

Authors

Katarzyna Talaga-Ćwiertnia
Paweł Krzyściak
Małgorzata Bulanda

References (21)
  1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1): 1–12.
  2. Cai Y, Venkatachalam I, Tee NW, et al. ECDC PPS study group, National Contact Points for the ECDC pilot point prevalence survey, Hospital Contact Points for the ECDC pilot point prevalence survey. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill. 2012; 17(46): 200–204.
  3. Pitout JDD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010; 70(3): 313–333.
  4. Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis. 2009; 49(6): 992–993.
  5. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3): 268–281.
  6. Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res. 2010; 15(12): 554–563.
  7. Averbuch D, Cordonnier C, Livermore DM, et al. ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013; 98(12): 1836–1847.
  8. Gniadkowski M, Żabicka D, Hryniewicz W: Guidelines on the selection of tests to determine the susceptibility of bacteria to antibiotics and chemotherapeutics 2009. Determination of the susceptibility of Gram-negative bacteria. Polish National Reference Centre for Antimicrobial Susceptibility Affairs — KORLD. http://korld.edu.pl/pdf/02-Rek2009Paleczki_z_rodziny_Enterobacteriaceae. (14.05.2015).
  9. R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, 2013. http://www.r-project.org/ (14.05.2015).
  10. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011; 1: 47.
  11. Rutkowska K, Przybyła M, Misiołek H. Health-care associated infection in the newly-opened intensive care unit. Anaesthesiol Intensive Ther. 2013; 45(2): 62–66.
  12. Misiewska-Kaczur A. Oddział intensywnej terapii [Intensive care unit]. W: Bulanda M, Wójkowska-Mach J (ed.): Zakażenia szpitalne w jednostkach opieki zdrowotnej [Hospital-acquired infections in healthcare centres]. PZWL, Warszawa. ; 2016: 262–284.
  13. Tajeddin E, Rashidan M, Razaghi M, et al. The role of the intensive care unit environment and health-care workers in the transmission of bacteria associated with hospital acquired infections. J Infect Public Health. 2016; 9(1): 13–23.
  14. Hryniewicz W, Kusza K, Ozorowski T, et al. Strategia zapobiegania lekooporności w oddziałach intensywnej terapii. Rekomendacje profilaktyki zakażeń w oddziałach intensywnej terapii [Strategy for preventing drug resistance in intensive care units. Recommendations for the prevention of infections in intensive care units], Warszawa 2013, www. mz gov pl/__data/assets/pdf_file/0017/5615/9astrategiazapobeigllo. ; 20130412: pdf.
  15. Sekowska A, Gospodarek E. Susceptibility of Klebsiella spp. to tigecycline and other selected antibiotics. Med Sci Monit. 2010; 16(6): BR193–BR196.
  16. Sękowska A, Gospodarek E, Kusza K. The prevalence of infections and colonisation with Klebsiella pneumoniae strains isolated in ICU patients. Anaesthesiol Intensive Ther. 2014; 46(4): 280–283.
  17. Sanitary conditions in Poland in 2015. http://gis.gov.pl/images/gis_stan_2015_internet_jb.pdf.
  18. Ojdana D, Sacha P, Olszańska D, et al. First Report of Klebsiella pneumoniae-Carbapenemase-3-Producing Escherichia coli ST479 in Poland. Biomed Res Int. 2015; 2015: 256028.
  19. Michalska AD, Sacha PT, Ojdana D, et al. Carbapenem-resistant strains from the family Enterobacteriaceae isolated in the period 2006-2011 from clinical specimens of patients treated at the university hospital in northeastern Poland. Med Dosw Mikrobiol. 2013; 65(1): 27–38.
  20. Franiczek R, Krzyżanowska B. ESBL-producing Escherichia coli isolated from bloodstream infections--antimicrobial susceptibility, conjugative transfer of resistance genes and phylogenetic origin. Adv Clin Exp Med. 2014; 23(6): 865–870.
  21. Rodloff AC, Dowzicky MJ. Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014). Chemotherapy. 2017; 62(1): 1–11.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, Świętokrzyska 73 St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl